New Mission, New Website coming soon! Learn more now.

Equities logo
Search
Close this search box.

Biotech Sector Turns Red-Hot on Alzheimer’s Treatment News

In Phase 3 trials, a Biogen / Eisai Alzheimer’s drug slowed cognitive decline by 27%.